Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated protein-protein interactions

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1781, Issue 9, 2008, Pages 558-562

  Lin, Fang Tsyr ^a   Lai, Yun Ju ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

LIM; LPA; LPA2 receptor; PDZ; Protein protein interactions; Zinc finger

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIM PROTEIN; LYSOPHOSPHATIDIC ACID 2 RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SODIUM PROTON EXCHANGE PROTEIN 2; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; PROTEIN BINDING; PROTEIN MOTIF;

AMINO ACID MOTIFS; ANIMALS; ENZYME ACTIVATION; HUMANS; PROTEIN BINDING; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION;

EID: 49949098520     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2008.04.013     Document Type: Review

References (77)

1. Contos J.J., Ishii I., and Chun J. Lysophosphatidic acid receptors. Mol. Pharmacol. 58 (2000) 1188-1196
2. Moolenaar W.H., van Meeteren L.A., and Giepmans B.N. The ins and outs of lysophosphatidic acid signaling. Bioessays 26 (2004) 870-881
3. Moolenaar W.H. Bioactive lysophospholipids and their G protein-coupled receptors. Exp. Cell Res. 253 (1999) 230-238
4. Moolenaar W.H. LPA: a novel lipid mediator with diverse biological actions. Trends Cell Biol. 4 (1994) 213-219
5. Mills G.B., and Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3 (2003) 582-591
6. Pasternack S.M., von Kugelgen I., Aboud K.A., Lee Y.A., Ruschendorf F., Voss K., Hillmer A.M., Molderings G.J., Franz T., Ramirez A., Nurnberg P., Nothen M.M., and Betz R.C. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat. Genet. 40 (2008) 329-334
7. Hecht J.H., Weiner J.A., Post S.R., and Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135 (1996) 1071-1083
8. An S., Bleu T., Hallmark O.G., and Goetzl E.J. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273 (1998) 7906-7910
9. Aoki J., Bandoh K., and Inoue K. A novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid with unsaturated fatty-acid moiety. Ann. N. Y. Acad. Sci. 905 (2000) 263-266
10. Noguchi K., Ishii S., and Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 278 (2003) 25600-25606
11. Lee C.W., Rivera R., Gardell S., Dubin A.E., and Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J. Biol. Chem. 281 (2006) 23589-23597
12. Tabata K., Baba K., Shiraishi A., Ito M., and Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem. Biophys. Res. Commun. 363 (2007) 861-866
13. Zhang C., Baker D.L., Yasuda S., Makarova N., Balazs L., Johnson L.R., Marathe G.K., McIntyre T.M., Xu Y., Prestwich G.D., Byun H.S., Bittman R., and Tigyi G. Lysophosphatidic acid induces neointima formation through PPARgamma activation. J. Exp. Med. 199 (2004) 763-774
14. McIntyre T.M., Pontsler A.V., Silva A.R., St Hilaire A., Xu Y., Hinshaw J.C., Zimmerman G.A., Hama K., Aoki J., Arai H., and Prestwich G.D. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 131-136
15. Xu J., Lai Y.J., Lin W.C., and Lin F.T. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J. Biol. Chem. 279 (2004) 10459-10468
16. Zhang H., Wang D., Sun H., Hall R.A., and Yun C.C. MAGI-3 regulates LPA-induced activation of Erk and RhoA. Cell Signal 19 (2007) 261-268
17. Oh Y.S., Jo N.W., Choi J.W., Kim H.S., Seo S.W., Kang K.O., Hwang J.I., Heo K., Kim S.H., Kim Y.H., Kim I.H., Kim J.H., Banno Y., Ryu S.H., and Suh P.G. NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation. Mol. Cell. Biol. 24 (2004) 5069-5079
18. Yamada T., Ohoka Y., Kogo M., and Inagaki S. Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs). J. Biol. Chem. 280 (2005) 19358-19363
19. Lin F.T., Lai Y.J., Makarova N., Tigyi G., and Lin W.C. The lysophosphatidic acid 2 receptor mediates down-regulation of Siva-1 to promote cell survival. J. Biol. Chem. 282 (2007) 37759-37769
20. Li C., Dandridge K.S., Di A., Marrs K.L., Harris E.L., Roy K., Jackson J.S., Makarova N.V., Fujiwara Y., Farrar P.L., Nelson D.J., Tigyi G.J., and Naren A.P. Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. J. Exp. Med. 202 (2005) 975-986
21. Yun C.C., Sun H., Wang D., Rusovici R., Castleberry A., Hall R.A., and Shim H. LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am. J. Physiol. Cell Physiol. 289 (2005) C2-C11
22. Contos J.J., Ishii I., Fukushima N., Kingsbury M.A., Ye X., Kawamura S., Brown J.H., and Chun J. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol. Cell Biol. 22 (2002) 6921-6929
23. Shida D., Watanabe T., Aoki J., Hama K., Kitayama J., Sonoda H., Kishi Y., Yamaguchi H., Sasaki S., Sako A., Konishi T., Arai H., and Nagawa H. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab. Invest. 84 (2004) 1352-1362
24. Kitayama J., Shida D., Sako A., Ishikawa M., Hama K., Aoki J., Arai H., and Nagawa H. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast. Cancer Res. 6 (2004) R640-R646
25. Fang X., Gaudette D., Furui T., Mao M., Estrella V., Eder A., Pustilnik T., Sasagawa T., Lapushin R., Yu S., Jaffe R.B., Wiener J.R., Erickson J.R., and Mills G.B. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann. N. Y. Acad. Sci. 905 (2000) 188-208
26. Schulte K.M., Beyer A., Kohrer K., Oberhauser S., and Roher H.D. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int. J. Cancer 92 (2001) 249-256
27. Umezu-Goto M., Kishi Y., Taira A., Hama K., Dohmae N., Takio K., Yamori T., Mills G.B., Inoue K., Aoki J., and Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158 (2002) 227-233
28. Boucharaba A., Serre C.M., Gres S., Saulnier-Blache J.S., Bordet J.C., Guglielmi J., Clezardin P., and Peyruchaud O. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 114 (2004) 1714-1725
29. Hur E.M., and Kim K.T. G protein-coupled receptor signalling and cross-talk: achieving rapidity and specificity. Cell. Signal. 14 (2002) 397-405
30. Maudsley S., Martin B., and Luttrell L.M. The origins of diversity and specificity in g protein-coupled receptor signaling. J. Pharmacol. Exp. Ther. 314 (2005) 485-494
31. Cho K.O., Hunt C.A., and Kennedy M.B. The rat brain postsynaptic density fraction contains a homolog of the Drosophila discs-large tumor suppressor protein. Neuron 9 (1992) 929-942
32. Kim E., Niethammer M., Rothschild A., Jan Y.N., and Sheng M. Clustering of Shaker-type K+ channels by interaction with a family of membrane-associated guanylate kinases. Nature 378 (1995) 85-88
33. Fanning A.S., and Anderson J.M. Protein-protein interactions: PDZ domain networks. Curr. Biol. 6 (1996) 1385-1388
34. Kornau H.C., Schenker L.T., Kennedy M.B., and Seeburg P.H. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 269 (1995) 1737-1740
35. Sato T., Irie S., Kitada S., and Reed J.C. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268 (1995) 411-415
36. Sheng M., and Sala C. PDZ domains and the organization of supramolecular complexes. Annu. Rev. Neurosci. 24 (2001) 1-29
37. Weinman E.J., and Shenolikar S. Regulation of the renal brush border membrane Na(+)-H+ exchanger. Annu. Rev. Physiol. 55 (1993) 289-304
38. Shenolikar S., and Weinman E.J. NHERF: targeting and trafficking membrane proteins. Am. J. Physiol. Renal. Physiol. 280 (2001) F389-F395
39. Weinman E.J., and Shenolikar S. The Na-H exchanger regulatory factor. Exp. Nephrol. 5 (1997) 449-452
40. Kleizen B., Braakman I., and de Jonge H.R. Regulated trafficking of the CFTR chloride channel. Eur. J. Cell. Biol. 79 (2000) 544-556
41. Weinman E.J., Hall R.A., Friedman P.A., Liu-Chen L.Y., and Shenolikar S. The association of NHERF adaptor proteins with g protein-coupled receptors and receptor tyrosine kinases. Annu. Rev. Physiol. 68 (2006) 491-505
42. Hall R.A., Ostedgaard L.S., Premont R.T., Blitzer J.T., Rahman N., Welsh M.J., and Lefkowitz R.J. A C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and cystic fibrosis transmembrane conductance regulator determines binding to the Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8496-8501
43. Hall R.A., Premont R.T., Chow C.W., Blitzer J.T., Pitcher J.A., Claing A., Stoffel R.H., Barak L.S., Shenolikar S., Weinman E.J., Grinstein S., and Lefkowitz R.J. The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature 392 (1998) 626-630
44. Shenolikar S., Minkoff C.M., Steplock D.A., Evangelista C., Liu M., and Weinman E.J. N-terminal PDZ domain is required for NHERF dimerization. FEBS Lett. 489 (2001) 233-236
45. Lau A.G., and Hall R.A. Oligomerization of NHERF-1 and NHERF-2 PDZ domains: differential regulation by association with receptor carboxyl-termini and by phosphorylation. Biochemistry 40 (2001) 8572-8580
46. Guggino S.E. Gates of Janus: cystic fibrosis and diarrhea. Trends Microbiol. 2 (1994) 91-94
47. Vazquez-Prado J., Basile J., and Gutkind J.S. Modular architecture and novel protein-protein interactions regulating the RGS-containing Rho guanine nucleotide exchange factors. Methods Enzymol. 390 (2004) 259-285
48. Bian D., Mahanivong C., Yu J., Frisch S.M., Pan Z.K., Ye R.D., and Huang S. The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration. Oncogene 25 (2006) 2234-2244
49. Dhanasekaran D.N. Transducing the signals: a G protein takes a new identity. Sci. STKE 2006 (2006) pe31
50. Gohla A., Harhammer R., and Schultz G. The G-protein G13 but not G12 mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho. J. Biol. Chem. 273 (1998) 4653-4659
51. Dobrosotskaya I., Guy R.K., and James G.L. MAGI-1, a membrane-associated guanylate kinase with a unique arrangement of protein-protein interaction domains. J. Biol. Chem. 272 (1997) 31589-31597
52. Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., and Lasky L.A. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J. Biol. Chem. 275 (2000) 21477-21485
53. Adamsky K., Arnold K., Sabanay H., and Peles E. Junctional protein MAGI-3 interacts with receptor tyrosine phosphatase beta (RPTP beta) and tyrosine-phosphorylated proteins. J. Cell Sci. 116 (2003) 1279-1289
54. Franklin J.L., Yoshiura K., Dempsey P.J., Bogatcheva G., Jeyakumar L., Meise K.S., Pearsall R.S., Threadgill D., and Coffey R.J. Identification of MAGI-3 as a transforming growth factor-alpha tail binding protein. Exp. Cell Res. 303 (2005) 457-470
55. He J., Bellini M., Inuzuka H., Xu J., Xiong Y., Yang X., Castleberry A.M., and Hall R.A. Proteomic analysis of beta1-adrenergic receptor interactions with PDZ scaffold proteins. J. Biol. Chem. 281 (2006) 2820-2827
56. Yao R., Natsume Y., and Noda T. MAGI-3 is involved in the regulation of the JNK signaling pathway as a scaffold protein for frizzled and Ltap. Oncogene 23 (2004) 6023-6030
57. Bach I. The LIM domain: regulation by association. Mech. Dev. 91 (2000) 5-17
58. Prasad K.V., Ao Z., Yoon Y., Wu M.X., Rizk M., Jacquot S., and Schlossman S.F. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 6346-6351
59. Wang Y., and Gilmore T.D. Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear. Biochim. Biophys. Acta 1593 (2003) 115-120
60. Zhao M.K., Wang Y., Murphy K., Yi J., Beckerle M.C., and Gilmore T.D. LIM domain-containing protein trip6 can act as a coactivator for the v-Rel transcription factor. Gene. Expr. 8 (1999) 207-217
61. Kassel O., Schneider S., Heilbock C., Litfin M., Gottlicher M., and Herrlich P. A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters. Genes Dev. 18 (2004) 2518-2528
62. Yi J., Kloeker S., Jensen C.C., Bockholt S., Honda H., Hirai H., and Beckerle M.C. Members of the Zyxin family of LIM proteins interact with members of the p130Cas family of signal transducers. J. Biol. Chem. 277 (2002) 9580-9589
63. Wang Y., and Gilmore T.D. LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochim. Biophys. Acta 1538 (2001) 260-272
64. Lai Y.J., Chen C.S., Lin W.C., and Lin F.T. c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol. Cell Biol. 25 (2005) 5859-5868
65. Murthy K.K., Clark K., Fortin Y., Shen S.H., and Banville D. ZRP-1, a zyxin-related protein, interacts with the second PDZ domain of the cytosolic protein tyrosine phosphatase hPTP1E. J. Biol. Chem. 274 (1999) 20679-20687
66. Lai Y.J., Lin W.C., and Lin F.T. PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration. J. Biol. Chem. 282 (2007) 24381-24387
67. Ye X., Ishii I., Kingsbury M.A., and Chun J. Lysophosphatidic acid as a novel cell survival/apoptotic factor. Biochim. Biophys. Acta 1585 (2002) 108-113
68. Radeff-Huang J., Seasholtz T.M., Matteo R.G., and Brown J.H. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J. Cell. Biochem. 92 (2004) 949-966
69. Goetzl E.J., Lee H., Dolezalova H., Kalli K.R., Conover C.A., Hu Y.L., Azuma T., Stossel T.P., Karliner J.S., and Jaffe R.B. Mechanisms of lysolipid phosphate effects on cellular survival and proliferation. Ann. N. Y. Acad. Sci. 905 (2000) 177-187
70. Hu X., Haney N., Kropp D., Kabore A.F., Johnston J.B., and Gibson S.B. Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB. J. Biol. Chem. 280 (2005) 9498-9508
71. Virag T., Elrod D.B., Liliom K., Sardar V.M., Parrill A.L., Yokoyama K., Durgam G., Deng W., Miller D.D., and Tigyi G. Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 63 (2003) 1032-1042
72. Deng W., Shuyu E., Tsukahara R., Valentine W.J., Durgam G., Gududuru V., Balazs L., Manickam V., Arsura M., VanMiddlesworth L., Johnson L.R., Parrill A.L., Miller D.D., and Tigyi G. The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology 132 (2007) 1834-1851
73. Fortin A., MacLaurin J.G., Arbour N., Cregan S.P., Kushwaha N., Callaghan S.M., Park D.S., Albert P.R., and Slack R.S. The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1. J. Biol. Chem. 279 (2004) 28706-28714
74. Py B., Slomianny C., Auberger P., Petit P.X., and Benichou S. Siva-1 and an alternative splice form lacking the death domain, Siva-2, similarly induce apoptosis in T lymphocytes via a caspase-dependent mitochondrial pathway. J. Immunol. 172 (2004) 4008-4017
75. Gudi R., Barkinge J., Hawkins S., Chu F., Manicassamy S., Sun Z., Duke-Cohan J.S., and Prasad K.V. Siva-1 negatively regulates NF-kappaB activity: effect on T-cell receptor-mediated activation-induced cell death (AICD). Oncogene 25 (2006) 3458-3462
76. Xue L., Chu F., Cheng Y., Sun X., Borthakur A., Ramarao M., Pandey P., Wu M., Schlossman S.F., and Prasad K.V. Siva-1 binds to and inhibits BCL-X(L)-mediated protection against UV radiation-induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6925-6930
77. Wojcikiewicz R.J. Regulated ubiquitination of proteins in GPCR-initiated signaling pathways. Trends Pharmacol. Sci. 25 (2004) 35-41